NASDAQ:MEDP - Medpace Stock Price, Forecast & News

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Monday, February, 24th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.10. The company earned $229.89 million during the quarter, compared to the consensus estimate of $221.73 million. Medpace had a net margin of 11.67% and a return on equity of 17.24%. Medpace's revenue for the quarter was up 19.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.76 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Medpace.

Medpace issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share (EPS) guidance of 3.24-3.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.28. The company issued revenue guidance of $975M - 1.005 billion, compared to the consensus revenue estimate of $977.76 million.

5 brokerages have issued 1-year target prices for Medpace's stock. Their forecasts range from $62.00 to $99.00. On average, they anticipate Medpace's stock price to reach $86.75 in the next twelve months. This suggests that the stock has a possible downside of 15.2%. View Analyst Price Targets for Medpace.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Headlines about MEDP stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medpace earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the stock's share price in the next several days. View News Stories for Medpace.

Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), PRA Health Sciences (PRAH), Exelixis (EXEL), BTG (BTGGF), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Alibaba Group (BABA), Adobe (ADBE), Baidu (BIDU), Paycom Software (PAYC), Veeva Systems (VEEV), Fortinet (FTNT), Roku (ROKU) and Arista Networks (ANET).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by many different of institutional and retail investors. Top institutional investors include Pendal Group Ltd (3.55%), State Street Corp (2.21%), Renaissance Technologies LLC (1.63%), Acadian Asset Management LLC (1.47%), Geode Capital Management LLC (1.19%) and Goldman Sachs Group Inc. (1.11%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., PNC Financial Services Group Inc., Marshall Wace LLP, Goldman Sachs Group Inc., AQR Capital Management LLC, SG Americas Securities LLC and Bowling Portfolio Management LLC. Company insiders that have sold Medpace company stock in the last year include Jesse J Geiger and Stephen P Ewald. View Insider Buying and Selling for Medpace.

MEDP stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Man Group plc, Renaissance Technologies LLC, California Public Employees Retirement System, Bank of Montreal Can, Great West Life Assurance Co. Can and McGuire Investment Group LLC. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $102.35.

Medpace has a market capitalization of $3.69 billion and generates $860.97 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

The official website for Medpace is http://www.medpace.com/.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]